FDA notifications. Pediatric formulation of lamivudine approved.
D000293:Adolescent; D002626:Chemistry, Pharmaceutical; D002648:Child; D002675:Child, Preschool; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use*; D010372:Pediatrics; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine